DaVita HealthCare Partners Inc. (NYSE:DVA) released its earnings results on Tuesday. The company reported $0.81 earnings per share for the quarter, missing analysts’ consensus estimates of $0.94 by ($0.13), Bloomberg Earnings reports. The firm had revenue of $3.92 billion during the quarter, compared to analyst estimates of $3.91 billion. DaVita HealthCare Partners had a return on equity of 14.02% and a net margin of 8.68%. The business’s revenue for the quarter was up 5.2% on a year-over-year basis. During the same quarter last year, the company earned $0.95 earnings per share.

Shares of DaVita HealthCare Partners (NYSE DVA) traded down $0.45 during trading hours on Tuesday, reaching $58.96. 2,017,774 shares of the company’s stock traded hands, compared to its average volume of 2,440,000. The company has a debt-to-equity ratio of 1.69, a quick ratio of 1.38 and a current ratio of 1.45. DaVita HealthCare Partners has a 52 week low of $53.58 and a 52 week high of $70.16. The firm has a market cap of $11,250.00, a P/E ratio of 16.46, a P/E/G ratio of 4.51 and a beta of 0.98.

A number of equities research analysts have weighed in on DVA shares. Jefferies Group LLC restated a “hold” rating and issued a $70.00 target price on shares of DaVita HealthCare Partners in a research report on Thursday, August 3rd. Zacks Investment Research raised DaVita HealthCare Partners from a “sell” rating to a “hold” rating in a report on Thursday, August 3rd. TheStreet cut DaVita HealthCare Partners from a “b” rating to a “c+” rating in a report on Wednesday, August 2nd. BidaskClub cut DaVita HealthCare Partners from a “sell” rating to a “strong sell” rating in a report on Saturday, August 5th. Finally, Royal Bank Of Canada reaffirmed a “hold” rating and issued a $64.00 price target on shares of DaVita HealthCare Partners in a report on Wednesday, September 6th. Four investment analysts have rated the stock with a sell rating, six have given a hold rating and one has assigned a buy rating to the company’s stock. The stock currently has an average rating of “Hold” and a consensus price target of $65.00.

DaVita HealthCare Partners announced that its Board of Directors has initiated a stock repurchase plan on Tuesday, October 10th that permits the company to buyback $1.50 billion in outstanding shares. This buyback authorization permits the company to repurchase shares of its stock through open market purchases. Shares buyback plans are generally an indication that the company’s leadership believes its shares are undervalued.

ILLEGAL ACTIVITY WARNING: “DaVita HealthCare Partners Inc. (DVA) Issues Earnings Results” was originally published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this story on another domain, it was stolen and reposted in violation of US & international copyright and trademark law. The legal version of this story can be read at https://www.thecerbatgem.com/2017/11/07/davita-healthcare-partners-inc-dva-issues-earnings-results.html.

About DaVita HealthCare Partners

DaVita Inc, formerly DaVita HealthCare Partners Inc, operates two divisions: DaVita Kidney Care (Kidney Care) and DaVita Medical Group (DMG). The Kidney Care division consists of its the United States dialysis and related lab services, its ancillary services and strategic initiatives, including its international operations, and its corporate administrative support.

Earnings History for DaVita HealthCare Partners (NYSE:DVA)

Receive News & Stock Ratings for DaVita HealthCare Partners Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DaVita HealthCare Partners Inc. and related stocks with our FREE daily email newsletter.